Canada Releases New Safety Information for Tarceva
December 19th, 2008 meg
Hoffmann-La Roche Limited, in consultation with Health Canada, has informed Canadian health care professionals of new important safety information regarding the use of TARCEVA® (erlotinib) in patients with moderate liver impairment and advanced cancer.
TARCEVA is used to treat patients with non-small cell lung cancer at an advanced stage in which chemotherapy has not helped to stop the disease.
A number of patients with liver impairment died during treatment or within 30 days of the last dose compared to patients with normal liver function.
The new safety information suggests that patients currently on or who have recently taken TARCEVA should have their liver function closely monitored by their doctor.
